D.E. Shaw & Co
UBX

D.E. Shaw & Co’s Unity Biotechnology UBX Stock Holding History

D.E. Shaw & Co’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,015
Closed -$15K – 5951
2021
Q4 		$15K Sell
1,015
-10,527
-91% -$230K ﹤0.01% 5312
2021
Q3 		$346K Buy
11,542
+6,032
+109% +$213K ﹤0.01% 4281
2021
Q2 		$256K Buy
+5,510
New +$265K ﹤0.01% 4348
2021
Q1 		– Sell
-1,555
Closed -$81K – 4505
2020
Q4 		$81K Buy
+1,555
New +$75K ﹤0.01% 3831
2020
Q3 		– Sell
-1,560
Closed -$135K – 4178
2020
Q2 		$135K Buy
+1,560
New +$116K ﹤0.01% 3855
2020
Q1 		– Sell
-3,471
Closed -$250K – 4280
2019
Q4 		$250K Buy
+3,471
New +$245K ﹤0.01% 3709
2018
Q4 		– Sell
-1,122
Closed -$183K – 3998
2018
Q3 		$183K Buy
+1,122
New +$185K ﹤0.01% 3571

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFVM
Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

D.E. Shaw & Co's UBX Position: Q1 2022 in Review

D.E. Shaw & Co sold out of Unity Biotechnology (UBX) in Q1 2022, closing a stake of 1,015 shares — an estimated $15K sold.

D.E. Shaw & Co first reported a position in UBX in Q3 2018 and held it in 7 quarters. The position peaked at $346K in Q3 2021. 70 funds tracked by Wall St. Rank hold UBX as of Q1 2022.

  • D.E. Shaw & Co reported no remaining Unity Biotechnology position as of Q1 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,015 Unity Biotechnology shares in Q1 2022, an estimated $15K.
  • D.E. Shaw & Co first reported a position in Unity Biotechnology in Q3 2018 and held it in 7 quarters.
  • D.E. Shaw & Co's Unity Biotechnology position peaked at $346K in Q3 2021.
  • 70 funds tracked by Wall St. Rank held Unity Biotechnology as of Q1 2022.

Based on D.E. Shaw & Co's 13F filing for Q1 2022, filed 16 May 2022.